CYP2D6*3 (A2549del), *4 (G1846A), *10 (C100T) and *17 (C1023T) genetic polymorphisms in Iranian breast cancer patients treated with adjuvant tamoxifen

There is controversy regarding the efficacy of tamoxifen in breast cancer patients who are carriers of cytochrome P450 2D6 (CYP2D6) gene polymorphisms. Poor metabolizer genotypes may not fully convert tamoxifen to its active metabolite endoxifen and thus have less exposure to anti-estrogen therapy....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Biomed Rep
Main Authors: Saghafi, Fatemeh, Salehifar, Ebrahim, Janbabai, Ghasem, Zaboli, Ehsan, Hedayatizadeh-Omran, Akbar, Amjadi, Omolbanin, Moradi, Siavash
Formato: Artigo
Idioma:Inglês
Publicado em: D.A. Spandidos 2018
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6176100/
https://ncbi.nlm.nih.gov/pubmed/30345040
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/br.2018.1145
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados